Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chinese Medicine for Residue Symptoms of COVID-19 Recovered Patients
NCT04924881Phase 2Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Jul 2021
- Primary completion
- Oct 2022
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of COVID Rehab Formula in post COVID-19 condition (PCC) (2 arms), sponsored by The Chinese University of Hong Kong. Primary endpoint: Fatigue Severity Score at 8 weeks. Started Jul 2021; status: completed.
02
Drugs
COVID Rehab Formula
03
Conditions
post COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT04924881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04924881.